Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Jazz Pharmaceuticals - Stock

Jazz Pharmaceuticals Stock

JAZZ
IE00B4Q5ZN47
A1JS1K

Price

101.27
Today +/-
+0
Today %
+0 %
P

Jazz Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Jazz Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Jazz Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Jazz Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Jazz Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Jazz Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Jazz Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Jazz Pharmaceuticals’s growth potential.

Jazz Pharmaceuticals Revenue, EBIT and net profit per share

DateJazz Pharmaceuticals RevenueJazz Pharmaceuticals EBITJazz Pharmaceuticals Net Income
2029e5.31 B undefined0 undefined1.36 B undefined
2028e5.17 B undefined2.25 B undefined1.56 B undefined
2027e4.89 B undefined2.15 B undefined1.48 B undefined
2026e4.67 B undefined2.01 B undefined1.41 B undefined
2025e4.44 B undefined1.93 B undefined1.34 B undefined
2024e4.13 B undefined1.76 B undefined1.19 B undefined
20233.83 B undefined659.38 M undefined414.83 M undefined
20223.66 B undefined108.9 M undefined-224.1 M undefined
20213.09 B undefined399.3 M undefined-329.7 M undefined
20202.36 B undefined514.2 M undefined238.6 M undefined
20192.16 B undefined532.4 M undefined523.4 M undefined
20181.89 B undefined657.7 M undefined447.1 M undefined
20171.62 B undefined528.8 M undefined487.8 M undefined
20161.49 B undefined593.2 M undefined396.8 M undefined
20151.32 B undefined541.4 M undefined329.5 M undefined
20141.17 B undefined236.9 M undefined58.4 M undefined
2013872.4 M undefined341.8 M undefined216.3 M undefined
2012586 M undefined197.8 M undefined288.6 M undefined
2011272.3 M undefined127.8 M undefined125 M undefined
2010173.8 M undefined57.8 M undefined32.8 M undefined
2009128.4 M undefined15.9 M undefined-6.8 M undefined
200867.5 M undefined-140.6 M undefined-184.3 M undefined
200765.3 M undefined-101.2 M undefined-138.8 M undefined
200644.9 M undefined-78.1 M undefined-81.3 M undefined
200521.4 M undefined-57.1 M undefined-85.2 M undefined
20040 undefined-25.4 M undefined-24.8 M undefined

Jazz Pharmaceuticals Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00.020.040.070.070.130.170.270.590.871.171.321.491.621.892.162.363.093.663.834.134.444.674.895.175.31
--109.5247.733.0891.0435.1657.23115.4448.8134.4012.9712.398.7416.8114.349.3530.9418.264.787.777.555.184.665.642.83
-80.9584.0986.1579.1092.1992.4994.8586.5288.3090.0292.3092.8893.2093.6094.0893.6985.7585.2188.63------
00.020.040.060.050.120.160.260.510.771.061.221.381.511.772.032.212.653.123.4000000
-0.03-0.06-0.08-0.1-0.140.020.060.130.20.340.240.540.590.530.660.530.510.40.110.661.761.932.012.152.250
--271.43-177.27-155.38-208.9611.7232.9546.6933.6239.1120.1440.8639.8532.6334.7624.6221.7512.902.9517.1942.4743.3643.0343.9143.61-
-0.02-0.09-0.08-0.14-0.18-0.010.030.130.290.220.060.330.40.490.450.520.24-0.33-0.220.411.191.341.411.481.561.36
-254.17-4.7170.3733.33-96.74-633.33290.63130.40-25.00-73.15467.2420.3622.98-8.2117.00-54.49-238.24-31.91-284.82187.9212.255.315.045.41-13.01
24.624.624.613.825.63039.446.860.261.662.66361.961.361.257.656.559.762.572.07000000
- - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Jazz Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Jazz Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Jazz Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Jazz Pharmaceuticals's financial health and stability.

Assets

Jazz Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Jazz Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Jazz Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Jazz Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
-24-85-59-138-184-63212528821657329396487447523238-329-224414
051010159877482133108113165216370278552629638
00000000-113-10-49-61-41-225-88-236-13669-292-260
3215123-24-5-3-5-81-60-6-202623-150-85175283-52
00.02-0.020.030.040.010.030.040.030.130.40.250.240.350.30.380.730.51.10.58
061212122401141832403944424342138270333
00000000913710814516017416418322627194177
-0.02-0.05-0.06-0.08-0.13-0.020.060.150.250.290.410.530.590.690.80.780.90.781.271.09
-1-1-1-3-28-6-4-5-22-16-239-36-183-114-131-182-379-45-498-42
-6-153-15-11-6-2-81-395-16-1,067-2-1,751-269-394-155-1,007-5,212-446-163
-5-152081602-75-3720-82833-1,567-155-26327-628-5,16652-120
00000000000000000000
00.090.0200.040.01-0.08-0.050.440.090.88-0.170.82-0.33-0.03-0.030.593.87-0.58-0.03
579910098257621625-10516-21-254-67-430-243-4613598-223
0.060.190.120.10.060.01-0.03-0.030.45-0.020.71-0.210.54-0.41-0.48-0.290.533.97-0.53-0.31
-------8.00--15.00-5.00-190.00-26.00-21.00-15.00-23.00-16.00-16.00-35.00-45.00-50.00
00000000000000000000
29-135824-78-9293730524947304-62220-76327420-466290624
-22.2-53.6-59.1-84.2-158.9-2254.2145.8227.3272.3168.6495.9409579.1667.4594.1520.3733773.81,049.05
00000000000000000000

Jazz Pharmaceuticals stock margins

The Jazz Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Jazz Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Jazz Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Jazz Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Jazz Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Jazz Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Jazz Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Jazz Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Jazz Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Jazz Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Jazz Pharmaceuticals Margin History

Jazz Pharmaceuticals Gross marginJazz Pharmaceuticals Profit marginJazz Pharmaceuticals EBIT marginJazz Pharmaceuticals Profit margin
2029e88.64 %0 %25.54 %
2028e88.64 %43.61 %30.19 %
2027e88.64 %43.91 %30.26 %
2026e88.64 %43.03 %30.17 %
2025e88.64 %43.36 %30.12 %
2024e88.64 %42.47 %28.87 %
202388.64 %17.2 %10.82 %
202285.23 %2.98 %-6.12 %
202185.76 %12.9 %-10.66 %
202093.7 %21.75 %10.09 %
201994.08 %24.63 %24.21 %
201893.57 %34.78 %23.64 %
201793.19 %32.67 %30.14 %
201692.92 %39.87 %26.67 %
201592.26 %40.87 %24.87 %
201489.99 %20.2 %4.98 %
201388.3 %39.18 %24.79 %
201286.62 %33.75 %49.25 %
201194.86 %46.93 %45.91 %
201092.17 %33.26 %18.87 %
200992.52 %12.38 %-5.3 %
200879.41 %-208.3 %-273.04 %
200786.37 %-154.98 %-212.56 %
200684.41 %-173.94 %-181.07 %
200580.37 %-266.82 %-398.13 %
200488.64 %0 %0 %

Jazz Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Jazz Pharmaceuticals earnings per share therefore indicates how much revenue Jazz Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Jazz Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Jazz Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Jazz Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Jazz Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Jazz Pharmaceuticals Revenue, EBIT and net profit per share

DateJazz Pharmaceuticals Sales per ShareJazz Pharmaceuticals EBIT per shareJazz Pharmaceuticals Earnings per Share
2029e84.27 undefined0 undefined21.52 undefined
2028e81.95 undefined0 undefined24.74 undefined
2027e77.58 undefined0 undefined23.48 undefined
2026e74.12 undefined0 undefined22.36 undefined
2025e70.47 undefined0 undefined21.23 undefined
2024e65.52 undefined0 undefined18.92 undefined
202353.2 undefined9.15 undefined5.76 undefined
202258.55 undefined1.74 undefined-3.59 undefined
202151.83 undefined6.69 undefined-5.52 undefined
202041.83 undefined9.1 undefined4.22 undefined
201937.53 undefined9.24 undefined9.09 undefined
201830.9 undefined10.75 undefined7.31 undefined
201726.41 undefined8.63 undefined7.96 undefined
201624.04 undefined9.58 undefined6.41 undefined
201521.03 undefined8.59 undefined5.23 undefined
201418.74 undefined3.78 undefined0.93 undefined
201314.16 undefined5.55 undefined3.51 undefined
20129.73 undefined3.29 undefined4.79 undefined
20115.82 undefined2.73 undefined2.67 undefined
20104.41 undefined1.47 undefined0.83 undefined
20094.28 undefined0.53 undefined-0.23 undefined
20082.64 undefined-5.49 undefined-7.2 undefined
20074.73 undefined-7.33 undefined-10.06 undefined
20061.83 undefined-3.17 undefined-3.3 undefined
20050.87 undefined-2.32 undefined-3.46 undefined
20040 undefined-1.03 undefined-1.01 undefined

Jazz Pharmaceuticals business model

Jazz Pharmaceuticals PLC is a global biopharmaceutical company specializing in treating life-threatening diseases. The company was founded in 2003 in Ireland and now operates in Europe, North America, and other parts of the world. Jazz's business model focuses on offering innovative therapies for diseases that have no cure or unsatisfactory existing treatments. The company has a well-planned pipeline of high-quality products, supported by excellent customer service and innovative marketing strategies. Jazz holds numerous patents for various medications that can be used for different medical purposes. The company offers four different medical specialties: hematology-oncology, narcolepsy, pain medicine, and psychiatric disorders. Its most well-known specialty is hematology-oncology, where Jazz concentrates on developing therapies for hematological cancers such as leukemia, lymphomas, and myeloma. Furthermore, Jazz provides medications for rare diseases such as Gaucher's disease and Fabry disease. In the field of pain medicine, Jazz Pharmaceuticals has developed specific therapies for patients with sleep disorders and pain. The company also offers treatments for depressive disorders and obsessive-compulsive disorders. Another important area for Jazz is the development of medications for patients suffering from narcolepsy, a condition that causes constant fatigue and sudden sleep attacks, significantly impacting daily life for many patients. One of Jazz Pharmaceuticals' most well-known products is Xyrem, which is used to treat narcolepsy. Xyrem is a potent sedative with a high potential for addiction and can only be prescribed by qualified doctors. Another key product from Jazz is Vyxeos, a medication for the treatment of acute myeloid leukemia, an aggressive form of blood cancer typically difficult to treat. Vyxeos is a dual-action medication that can significantly improve the survival chances of leukemia patients. Jazz Pharmaceuticals is a global leader in hematology-oncology and has become a significant player in the market for medical therapies in recent years. The company currently employs over 1,500 employees and is listed on the NASDAQ. Its headquarters are located in Dublin, Ireland. Jazz Pharmaceuticals is dedicated to supporting patients worldwide with high-quality medical products and services. Jazz Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Jazz Pharmaceuticals SWOT Analysis

Strengths

Jazz Pharmaceuticals PLC boasts a diverse range of innovative pharmaceutical products, which contributes to their competitive advantage in the market. Their strong portfolio includes market-leading drugs and therapeutics, allowing them to cater to different patient needs and maintain a significant market share.

The company has a well-established research and development division dedicated to discovering new treatments and improving existing ones. This continuous focus on innovation and development enables Jazz Pharmaceuticals PLC to stay ahead of competitors and maintain a strong pipeline of potential blockbuster drugs.

Weaknesses

Jazz Pharmaceuticals PLC's success is heavily reliant on a few key products, which exposes them to market volatility and patent expirations. Any adverse events related to their main products could significantly affect the company's financial performance and overall market position.

While Jazz Pharmaceuticals PLC has a strong presence in certain markets, their geographic reach is relatively limited compared to some larger pharmaceutical companies. This narrow market presence can limit their growth potential and make them susceptible to regional economic or regulatory changes.

Opportunities

Jazz Pharmaceuticals PLC can seize opportunities by expanding their sales and operations into emerging markets. These regions offer untapped potential for growth, and by adapting their products to suit local needs, the company can establish a foothold in these markets and drive revenue expansion.

Strategic acquisitions and partnerships can provide Jazz Pharmaceuticals PLC with access to new technologies, markets, or capabilities. Such collaborations can enhance their product offerings, broaden their customer base, and strengthen their competitive position within the industry.

Threats

The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Jazz Pharmaceuticals PLC faces the constant threat of competitors launching similar drugs or therapies, which could impact their market position and financial performance.

As a pharmaceutical company, Jazz Pharmaceuticals PLC must comply with stringent regulations imposed by health authorities and regulatory bodies. Failure to meet these requirements can lead to delays in product approvals, increased costs, and potential legal repercussions, posing a significant threat to their operations.

Jazz Pharmaceuticals valuation based on historical P/E ratio, EBIT, and P/S ratio.

Jazz Pharmaceuticals shares outstanding

The number of shares was Jazz Pharmaceuticals in 2023 — This indicates how many shares 72.066 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Jazz Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Jazz Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Jazz Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Jazz Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Jazz Pharmaceuticals Stock splits

In Jazz Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Jazz Pharmaceuticals.

Jazz Pharmaceuticals Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20244.26 2.68  (-37.13 %)2024 Q1
12/31/20235.29 5.02  (-5.07 %)2023 Q4
9/30/20235.03 4.84  (-3.79 %)2023 Q3
6/30/20234.52 4.51  (-0.23 %)2023 Q2
3/31/20234.32 3.95  (-8.66 %)2023 Q1
12/31/20220.33 -0.07  (-121.41 %)2022 Q4
9/30/20224.75 5.17  (8.75 %)2022 Q3
6/30/20224.28 4.3  (0.58 %)2022 Q2
3/31/20223.92 3.73  (-4.77 %)2022 Q1
12/31/20213.72 4.21  (13.31 %)2021 Q4
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Jazz Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

62

👫 Social

67

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees55
Percentage of women in management—
Percentage of Asian employees18
Share of Asian management—
Percentage of Hispanic/Latino employees4
Hispano/Latino Management share—
Percentage of Black employees5
Black Management Share—
Percentage of white employees67
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Jazz Pharmaceuticals Stock Shareholders

%
Name
Stocks
Change
Date
8.85 % BlackRock Institutional Trust Company, N.A.5,578,88985,12312/31/2023
3.84 % State Street Global Advisors (US)2,421,12596,07712/31/2023
3.72 % LSV Asset Management2,343,227-28,95012/31/2023
2.24 % Capital World Investors1,414,5111,414,5113/31/2024
2.07 % Columbia Threadneedle Investments (US)1,304,5929,15212/31/2023
2.04 % JP Morgan Asset Management1,288,014-52,60912/31/2023
2.03 % Wellington Management Company, LLP1,280,197-388,31412/31/2023
2.01 % Polaris Capital Management, LLC1,267,46027,10012/31/2023
10.09 % The Vanguard Group, Inc.6,363,74832,5871/5/2024
1.95 % Renaissance Technologies LLC1,231,574-76,04112/31/2023
1
2
3
4
5
...
10

Jazz Pharmaceuticals Executives and Management Board

Mr. Bruce Cozadd59
Jazz Pharmaceuticals Chairman of the Board, Chief Executive Officer (since 2003)
Compensation 17.33 M
Ms. Renee Gala51
Jazz Pharmaceuticals President, Chief Operating Officer
Compensation 5.03 M
Dr. Robert Iannone56
Jazz Pharmaceuticals Executive Vice President, Global Head of Research and Development
Compensation 4.86 M
Ms. Kimberly Sablich54
Jazz Pharmaceuticals Executive Vice President, General Manager - US
Compensation 4.3 M
Ms. Neena Patil48
Jazz Pharmaceuticals Executive Vice President, Chief Legal Officer
Compensation 3.21 M
1
2
3
4

Jazz Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Evercore Inc A - Stock
Evercore Inc A
SupplierCustomer0,900,40-0,02-0,78-0,340,39
Ligand Pharmaceuticals - Stock
Ligand Pharmaceuticals
SupplierCustomer0,730,920,67-0,65-0,410,07
Owens & Minor - Stock
Owens & Minor
SupplierCustomer0,660,400,56-0,070,390,44
Omnicom - Stock
Omnicom
SupplierCustomer0,650,550,470,570,520,49
Financiere de Tubize - Stock
Financiere de Tubize
SupplierCustomer0,630,700,860,500,07-0,10
Thermo Fisher Scientific - Stock
Thermo Fisher Scientific
SupplierCustomer0,550,690,61-0,53-0,70-0,13
Codiak BioSciences - Stock
Codiak BioSciences
SupplierCustomer0,520,560,42-0,710,03-
Clinigen Group - Stock
Clinigen Group
SupplierCustomer0,490,270,260,620,55-
Springworks Therapeutics - Stock
Springworks Therapeutics
SupplierCustomer0,410,870,58-0,420,210,58
AmerisourceBergen - Stock
AmerisourceBergen
SupplierCustomer0,23-0,150,460,910,160,13
1
2

Jazz Pharmaceuticals stock: Frequently Asked Questions

What values and corporate philosophy does Jazz Pharmaceuticals represent?

Jazz Pharmaceuticals PLC represents values of innovation, integrity, and patient-centered healthcare. With a corporate philosophy focused on improving the lives of patients, Jazz Pharmaceuticals operates with a commitment to discovering, developing, and delivering meaningful solutions in the field of neuroscience and oncology. The company strives to address unmet medical needs and enhance patient outcomes through research and development of novel therapies. Jazz Pharmaceuticals PLC emphasizes collaboration, ethical practices, and a drive for excellence in every aspect of its operations. Its dedication to these values has made it a recognized leader in the pharmaceutical industry.

In which countries and regions is Jazz Pharmaceuticals primarily present?

Jazz Pharmaceuticals PLC is primarily present in various countries and regions around the world. The company operates in the United States, Europe, and other international markets. With its headquarters in Dublin, Ireland, Jazz Pharmaceuticals has a significant presence in North America, including the United States and Canada. Additionally, the company has expanded its operations in Europe, serving countries such as Germany, France, Italy, Spain, and the United Kingdom, among others. Jazz Pharmaceuticals PLC continues to focus on global growth and has established partnerships and collaborations in different regions to enhance its presence and reach in the pharmaceutical market.

What significant milestones has the company Jazz Pharmaceuticals achieved?

Jazz Pharmaceuticals PLC has achieved several significant milestones throughout its history. One notable achievement includes the successful development and FDA approval of their flagship product, Xyrem, which is used to treat narcolepsy. Another milestone for the company was the acquisition of Celator Pharmaceuticals, which expanded their oncology portfolio. Additionally, Jazz Pharmaceuticals PLC received FDA approval for Defitelio, an innovative treatment for a rare and life-threatening post-transplant condition known as hepatic veno-occlusive disease. These milestones demonstrate Jazz Pharmaceuticals PLC's commitment to developing innovative therapies and expanding their presence in the pharmaceutical industry.

What is the history and background of the company Jazz Pharmaceuticals?

Jazz Pharmaceuticals PLC is a renowned biopharmaceutical company with a rich history and background. Established in 2003, Jazz Pharmaceuticals has quickly emerged as a global leader in developing and commercializing innovative medicines to address unmet medical needs. The company focuses on complex diseases and conditions, primarily in the areas of sleep and hematology/oncology. Jazz Pharmaceuticals PLC has built a strong reputation for its commitment to scientific excellence, patient-centered approaches, and fostering collaborations worldwide. With a diverse portfolio of breakthrough treatments, the company continues to strive for advancements in patient care and improve the quality of life for individuals around the globe.

Who are the main competitors of Jazz Pharmaceuticals in the market?

The main competitors of Jazz Pharmaceuticals PLC in the market include Biogen Inc., Alexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.

In which industries is Jazz Pharmaceuticals primarily active?

Jazz Pharmaceuticals PLC is primarily active in the pharmaceutical industry.

What is the business model of Jazz Pharmaceuticals?

Jazz Pharmaceuticals PLC operates under a business model focused on the development and commercialization of innovative specialty pharmaceuticals. The company specializes in the identification and acquisition of highly-differentiated products to address unmet medical needs. Jazz Pharmaceuticals PLC leverages its expertise in medical research, regulatory affairs, and commercialization to bring these products to market and improve patient outcomes. By prioritizing research and development, strategic partnerships, and targeted marketing efforts, the company aims to provide effective and safe treatments to patients in need. Jazz Pharmaceuticals PLC is committed to advancing healthcare and remains dedicated to its mission of improving and prolonging patients' lives through innovative pharmaceutical solutions.

What is the P/E ratio of Jazz Pharmaceuticals 2024?

The Jazz Pharmaceuticals P/E ratio is 6.12.

What is the P/S ratio of Jazz Pharmaceuticals 2024?

The Jazz Pharmaceuticals P/S ratio is 1.77.

What is the AlleAktien quality score of Jazz Pharmaceuticals?

The AlleAktien quality score for Jazz Pharmaceuticals is 5/10.

What is the revenue of Jazz Pharmaceuticals 2024?

The expected Jazz Pharmaceuticals revenue is 4.13 B USD.

How high is the profit of Jazz Pharmaceuticals 2024?

The expected Jazz Pharmaceuticals profit is 1.19 B USD.

What is the business model of Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC is a biopharmaceutical company based in Dublin, Ireland. The company specializes in the development and marketing of drugs for the treatment of rare and complex diseases. The business strategy of Jazz Pharmaceuticals is based on a product portfolio that focuses on four core areas: sleep disorders, oncology, neuropathic pain, and hemophilia. Each area is characterized by a combination of internal research and development programs, as well as acquisitions and licensing agreements. The sleep disorders area includes Jazz Pharmaceuticals' flagship product, Xyrem. The product is an oral solution used to treat cataplexy in adult patients with narcolepsy. Xyrem is the only drug approved by the US Food and Drug Administration (FDA) to treat the symptoms of narcolepsy. Jazz Pharmaceuticals' oncology portfolio includes Erwinase, Asparaginase Erwinia chrysanthemi, among others. This is used to treat acute lymphoblastic leukemia (ALL). Other products in this area include Defitelio and Vyxeos, medications for treating complications in stem cell transplants or acute myeloid leukemia (AML). The neuropathic pain portfolio includes medications such as R-Lipoic Acid, a lipoic acid preparation used to treat diabetic neuropathy. Definitive remnants of burning pain associated with peripheral neuropathy and postherpetic neuralgia are also treated. Jazz Pharmaceuticals also has a product portfolio in the field of hemophilia. The company markets Recombinate, a recombinant human factor VIII preparation for the treatment of hemophilia A, as well as other products for the treatment of hemophilia. In addition to these four core areas, Jazz Pharmaceuticals also has a portfolio of medications used to treat opioid addiction, including the drug Lucemyra. Jazz Pharmaceuticals' business model is based on the development of innovative products for the treatment of rare and complex diseases. The company has a strong presence in the US and European markets and is actively working to expand its presence in other regions through partnerships and acquisitions. Jazz Pharmaceuticals uses a multi-channel strategy to market and distribute its products. The company works closely with doctors, medical professionals, and patient groups to ensure that its medications are made accessible to patients. Overall, Jazz Pharmaceuticals is working to improve the health and well-being of patients suffering from rare and complex diseases. The company is committed to innovation, excellent research and development, and a strong patient focus.

What is the Jazz Pharmaceuticals dividend?

Jazz Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Jazz Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Jazz Pharmaceuticals or the company does not pay out a dividend.

What is the Jazz Pharmaceuticals ISIN?

The ISIN of Jazz Pharmaceuticals is IE00B4Q5ZN47.

What is the Jazz Pharmaceuticals WKN?

The WKN of Jazz Pharmaceuticals is A1JS1K.

What is the Jazz Pharmaceuticals ticker?

The ticker of Jazz Pharmaceuticals is JAZZ.

How much dividend does Jazz Pharmaceuticals pay?

Over the past 12 months, Jazz Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Jazz Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Jazz Pharmaceuticals?

The current dividend yield of Jazz Pharmaceuticals is .

When does Jazz Pharmaceuticals pay dividends?

Jazz Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Jazz Pharmaceuticals?

Jazz Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Jazz Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Jazz Pharmaceuticals located?

Jazz Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Jazz Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Jazz Pharmaceuticals from 7/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/9/2024.

When did Jazz Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/9/2024.

What was the dividend of Jazz Pharmaceuticals in the year 2023?

In the year 2023, Jazz Pharmaceuticals distributed 0 USD as dividends.

In which currency does Jazz Pharmaceuticals pay out the dividend?

The dividends of Jazz Pharmaceuticals are distributed in USD.

Other fundamentals and analyses of Jazz Pharmaceuticals in the deep dive.

Our stock analysis for Jazz Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Jazz Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.